lunsumio
roche registration gmbh - mosunetuzumab - limfoma, follicular - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
upstaza
ptc therapeutics international limited - eladocagene exuparvovec - amino acid metaboliżmu, Żbalji inborn - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.
roctavian
biomarin international limited - valoctocogene roxaparvovec - sustanzi kontra l-emorraġija - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).
livtencity
takeda pharmaceuticals international ag ireland branch - maribavir - infezzjonijiet taċ-ċitomegalovirus - antivirali għal użu sistemiku - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu adattat ta ' aġenti antivirali.
hemgenix
csl behring gmbh - etranacogene dezaparvovec - hemofilja b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.
votrient
novartis europharm limited - pazopanib - karċinoma, Ċellula renali - aġenti antineoplastiċi - tal-kliewi-karċinoma taċ-ċellola (rcc)votrient huwa indikat fl-adulti għall-ewwel linja ta ' trattament ta avvanzat tal-kliewi-karċinoma taċ-ċellola (rcc) u għall-pazjenti li rċevew terapija minn qabel b'ċitokini għal marda avvanzata. sarkoma tat-tessuti rotob (sts)votrient huwa indikat għall-kura ta 'pazjenti adulti b'selettiv sottotipi ta' sarkoma tat-tessuti rotob (sts) u li jkunu ħadu l-kimoterapija qabel, għal mard metastatiku jew li għamlu progress fi żmien 12-il xahar ta'wara (neo)terapija miżjuda. l-effikaċja u s-sigurtà għandhom biss ġewx stabbiliti f'ċerti sts istoloġika tat-tumur sottotipi.
polivy
roche registration gmbh - polatuzumab vedotin - limfoma, b-cell - aġenti antineoplastiċi - polivy flimkien ma bendamustine u rituximab huwa indikat għall-kura ta ' pazjenti adulti b'reġgħet tfaċċat/refrattarja b kbira mxerrda-cell lymphoma (dlbcl) li mhumiex kandidati għall-trapjant ta'ċelloli staminali ematopojetiċi. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).
truscient
zoetis belgium sa - dibotermin alfa - proteini morfogenetiċi għall-għadam - klieb - aġent osteoindużiv għall-użu fit-trattament ta 'ksur tal-għadam fit-tul bħala addizzjoni għal kura kirurġika standard bl-użu ta' tnaqqis fil-fratturi miftuħ fil-klieb.
prialt
esteve pharmaceuticals gmbh - ziconotide - injections, spinal; pain - analġeżiċi - ziconotide huwa indikat għall-kura ta 'uġigħ sever u kroniku f'pazjenti li jeħtieġu analġeżija intrateġika (it).
inbrija
acorda therapeutics ireland limited - levodopa - marda ta 'parkinson - mediċini kontra l-parkinson - inbrija huwa indikat għat-trattament intermittenti ta episodiċi oxxillazzjonijiet motorji (off episodji) f'pazjenti adulti bil-marda ta ' parkinson (pd) li kienu kkurati bil-levodopa/dopa-decarboxylase inibitur.